This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Destiny Pharma Yönetim

Yönetim kriter kontrolleri 3/4

Destiny Pharma's CEO is Chris Tovey, appointed in Sep 2023, has a tenure of less than a year. total yearly compensation is £123.00K, comprised of 89.4% salary and 10.6% bonuses, including company stock and options. directly owns 0.042% of the company’s shares, worth €1.40K. The average tenure of the management team and the board of directors is 3.4 years and 6.3 years respectively.

Anahtar bilgiler

Chris Tovey

İcra Kurulu Başkanı

UK£123.0k

Toplam tazminat

CEO maaş yüzdesi89.4%
CEO görev süresiless than a year
CEO sahipliği0.04%
Yönetim ortalama görev süresi3.4yrs
Yönetim Kurulu ortalama görev süresi6.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Chris Tovey'un ücretlendirmesi Destiny Pharma'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Dec 31 2023UK£123kUK£110k

-UK£6m

Tazminat ve Piyasa: Chris's total compensation ($USD157.25K) is below average for companies of similar size in the German market ($USD531.21K).

Tazminat ve Kazançlar: Insufficient data to compare Chris's compensation with company performance.


CEO

Chris Tovey (59 yo)

less than a year

Görev süresi

UK£123,000

Tazminat

Mr. Christopher John Tovey, also known as Chris, BSc, serves as Chief Executive Officer & Director of Destiny Pharma plc since September 1, 2023. He had been the Chief Operating Officer at GW Pharmaceutica...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Christopher Tovey
CEO & Directorless than a yearUK£123.00k0.042%
£ 1.9k
William Love
Founder27.6yrsUK£250.00k6.8%
£ 309.2k
Shaun Claydon
CFO, Company Secretary & Director5.8yrsUK£270.00k0.025%
£ 1.2k
Debra Barker
Interim CMO & Senior Independent Directorless than a yearUK£213.00k0.092%
£ 4.2k

3.4yrs

Ortalama Görev Süresi

60.5yo

Ortalama Yaş

Deneyimli Yönetim: D89's management team is considered experienced (3.4 years average tenure).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Christopher Tovey
CEO & Directorless than a yearUK£123.00k0.042%
£ 1.9k
William Love
Founderno dataUK£250.00k6.8%
£ 309.2k
Shaun Claydon
CFO, Company Secretary & Director5.8yrsUK£270.00k0.025%
£ 1.2k
Debra Barker
Interim CMO & Senior Independent Director4.6yrsUK£213.00k0.092%
£ 4.2k
Anthony Nigel Rudd
Independent Chairman8yrsUK£34.00k3.93%
£ 178.7k
Richard Proctor
Member of Scientific Advisory Board6.3yrsVeri yokVeri yok
Nigel Brooksby
Non-Executive Director2.2yrsUK£41.00k0.36%
£ 16.6k
Vance Fowler
Member of Scientific Advisory Board6.3yrsVeri yokVeri yok
David Roblin
Chair of the Scientific Advisory Board6.3yrsUK£10.66kVeri yok
Leonard Mermel
Member of Scientific Advisory Board6.3yrsVeri yokVeri yok
Glenn J. Whitman
Member of Scientific Advisory Board6.3yrsVeri yokVeri yok
E Dellinger
Member of Scientific Advisory Boardno dataVeri yokVeri yok

6.3yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: D89's board of directors are considered experienced (6.3 years average tenure).